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ABSTRACT
Aspiration pneumonia, necrotising pneumonia and primary lung abscess are complications arising from
the aspiration of infectious material from the oral cavity or stomach. There is limited information on
optimal antibacterial therapeutic regimens. Patients with pulmonary infection following aspiration
(n ¼ 95) were included in a prospective, open, randomised, comparative multicentre trial to compare
the safety, clinical and bacteriological efﬁcacy of ampicillin + sulbactam vs. clindamycin ± cephalosp-
orin. Treated patients (n ¼ 70) received sequential antibiotic therapy with either ampicillin + sulbactam
(n ¼ 37) or clindamycin (n ¼ 33), with or without a second- or third-generation cephalosporin,
administered until the complete resolution of clinical and radiological abnormalities. Deﬁnite or
presumptive pathogens were isolated from 58 patients. Mean duration of therapy was 22.7 days for
ampicillin + sulbactam and 24.1 days for clindamycin. In patients treated with ampicillin + sulbactam,
the clinical response was 73.0% at the end of therapy and 67.5% 7–14 days after therapy. For
clindamycin, the rates were 66.7% and 63.5%, respectively. Bacteriological response was similar in both
treatment arms. Nine patients died (12.9%), with a Simpliﬁed Acute Physiology Score of > 30 points
being the only signiﬁcant predictive factor for therapeutic failure. Ampicillin + sulbactam and
clindamycin ± cephalosporin were both well-tolerated and proved equally effective in the treatment
of aspiration pneumonia and lung abscess.
Keywords Aspiration pneumonia, lung abscess, anaerobic infection, antimicrobial treatment, broncho-
scopy, pneumonia
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INTRODUCTION
Pneumonia and primary lung abscess are import-
ant complications following aspiration of infec-
tious material from the oropharynx or stomach,
and can result in life-threatening complications,
including severe haemoptysis [1]. Fatality rates of
up to 15–20% have been reported [2,3]. The
principal therapeutic strategy for aspiration pneu-
monia and lung abscess is a prolonged course of
antibiotic therapy. Despite a multitude of risk
factors predisposing to aspiration, such as
compromised consciousness and dysphagia [4],
alcoholism, seizure disorders, drug overdosage,
general anaesthesia, protracted vomiting, neuro-
logical disorders and stroke [5,6], aspiration
pneumonia is diagnosed infrequently. Initial signs
of aspiration pneumonia resemble those of other
forms of pneumonia and pneumonitis. Cavitation
of lung parenchyma or production of putrid
sputum usually only occur 8–14 days after an
aspiration event [4,7]. The time course of the
disease suggests that the frequency of aspiration
pneumonia may be underestimated.
Although numerous studies have implica-
ted anaerobic microorganisms as key pathogens
in aspiration pneumonia [8–10], the abscess
ﬂora generally comprises a mixed spectrum of
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microbes, including micro-aerophilic and aerobic
bacteria. Penicillin G has long been the drug of
choice, because of its in-vitro activity against
anaerobes and its favourable clinical efﬁcacy. In
newer trials, penicillin G was outperformed by
clindamycin, probably because of an increasing
number of penicillin-resistant strains of Bactero-
ides spp. [9,10].
Although several different antibiotics are
recommended for the treatment of aspiration
pneumonia, including third-generation cephalo-
sporins, ﬂuoroquinolones and piperacillin [11], no
data are available to date that support the use of
any of these regimens on the basis of recent and
adequate clinical trials, with sufﬁcient numbers of
patients, that take into account the changing
pattern of antimicrobial resistance. To further
clarify the role of penicillin- and clindamycin-
based antibacterial regimens, the present study
compared the efﬁcacy and safety of ampicillin
combined with the b-lactamase inhibitor sulbac-
tam vs. clindamycin in patients with aspiration
pneumonia and primary lung abscess. Consider-
ing its lack of activity against Gram-negative
bacteria, clindamycin was optionally combined
with a second- or third-generation cephalosporin
according to microbiological ﬁndings. Risk factors
for an unfavourable outcome of antibiotic therapy
in aspiration pneumonia were also assessed, since
the literature addressing this aspect is scarce and
inconclusive.
MATERIALS AND METHODS
Study subjects and study design
From April 1995 to August 1998, eight German centres
participated in an open, randomised, comparative and pros-
pective multicentre study with two treatment groups, with at
least 80 individuals in the intention-to-treat (ITT) population.
Patients hospitalised with radiographic and clinical signs of
aspiration pneumonia or primary lung abscess were random-
ised to receive sequential therapy (with a switch from
intravenous to oral therapy) consisting of either ampicil-
lin + sulbactam or clindamycin ± cephalosporin. A bacterio-
logical evaluation was performed before therapy. Antibiotics
were administered until the complete resolution of clinical and
radiological abnormalities. Clinical response as the primary
endpoint, bacteriological response as the secondary endpoint,
and safety were evaluated at the end of therapy and at a ﬁnal
visit. Demographic and clinical characteristics were used to
evaluate prognostic factors. The investigation was approved
by the Ethics Committees of all participating institutions.
Written informed consent in accordance with the Declaration
of Helsinki was obtained before therapy.
Patients
All patients who were randomised and received at least one
dose of study drug were evaluated for safety. The ITT
population contained all patients who were monitored for at
least 48 h, received a minimum of six doses of medication, and
did not violate exclusion criteria in any fundamental way. The
according-to-protocol (ATP) population comprised all patients
of the ITT population who received a full course (at least
6 days) of study drugs according to protocol. Valid values
with regard to primary and secondary endpoints were
required.
Inclusion criteria
Patients with a minimum age of 18 years were included if
they had radiographic signs of a new inﬁltrate in accordance
with community-acquired or nosocomial pneumonia and ⁄ or
pulmonary abscess after established or strongly suspected
aspiration. At least two of the symptoms of cough, chest
pain, dyspnoea, dullness on percussion or pulmonary rales
needed to be present, in combination with at least one
clinical criterion: fever (> 38C), hypothermia (< 36.5C),
leukocytosis (> 10 ⁄nL), leukopenia (< 4 ⁄nL), a left-shift of
> 10%, or purulent sputum or secretion from trachea or
bronchii.
Exclusion criteria
Patients were excluded if post-stenotic pneumonia, infarc-
tion pneumonia, tuberculosis, endocarditis and ⁄ or intraven-
ous drug abuse were present, or if they had received
mechanical ventilation for > 48 h or antibiotic treatment
within 24 h before inclusion. Pregnant or lactating women
were excluded. Patients with severely impaired renal or
liver function, and granulocytopenia, were disqualiﬁed from
inclusion.
Study medication
Therapy was given intravenously for at least 6 days, and was
continued orally. The minimum treatment period was 6 days.
Patients received 2 g of ampicillin plus 1 g of sulbactam three-
times-daily, intravenously. Oral therapy consisted of 750 mg of
ampicillin + sulbactam twice-daily. Clindamycin was given,
intravenously at a dose of 600 mg three-times-daily. The use of
a second- or third-generation cephalosporin was required in
nosocomial infections and was added optionally according to
the pattern of pathogens isolated in community-acquired
disease. Because of a higher frequency of adverse effects with
oral therapy, clindamycin was continued at an oral dose of
300 mg three-times-daily.
Collection of clinical data
Clinical data were obtained before therapy, at follow-up visits
during treatment, at an examination at the end of therapy, and
at a ﬁnal examination 7–14 days after the end of study
medication.
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Bacteriological sampling
Valid material for microbiological procedures was obtained
from each patient before and, if applicable, at the end of
therapy. Bronchoscopy was attempted whenever possible.
Gram-staining, and aerobic and anaerobic cultures, were
performed. Sputum samples and bronchial secretions were
considered to be representative for aerobic bacteria if they
demonstrated > 25 polymorphonuclear leukocytes and < 10
squamous epithelial cells ⁄ low-power ﬁeld. Bacteria isolated
from bronchoalveolar lavage, protected specimen brush and
transthoracic puncture were considered to be deﬁnite causa-
tive pathogens, while organisms recovered from sputum
cultures and bronchial aspirates were considered to be
presumptive causative organisms. Anaerobic cultures were
performed for material from bronchoalveolar lavage, protected
specimen brush and transthoracic puncture only. Microbiolo-
gical testing was carried out at the laboratory institutions of
each clinical centre.
Evaluation of efﬁcacy
Evaluation of clinical response was performed at the end of
therapy and after a further 7–14 days. Resolution of radio-
graphic abnormalities to a range that was considered normal
for the individual patient and complete normalisation of
clinical signs and laboratory parameters of infection (i.e., leu-
kocytes, differential count, C-reactive protein) were consid-
ered to represent a cure. Partial resolution of abnormalities in
radiographic, clinical and laboratory ﬁndings was classiﬁed
as an improvement. In statistical evaluation, any ratings of
cure or improvement were considered to constitute a
response, and any signs of failure to constitute no response.
Eradication, suspected eradication and eradication with
colonisation were considered to represent a response in
the statistical analysis of bacteriological efﬁcacy, whereas
persistence, relapse and reinfection were deﬁned as no
response.
Statistical analysis
Statistical analysis of the efﬁcacies of both treatment options
was based on clinical and bacteriological response rates. For
primary and secondary endpoints, 95% conﬁdence intervals
were calculated (Pearson–Clopper) for each treatment arm,
and both study medications were compared with a one-
sided equivalence test according to Farrington and Manning
[12], using a 10% and 15% equivalence range (explorative
analysis). An adjusted analysis was performed using the test
of Yanagawa et al. [13]. The ATP analysis was considered to
be the main analysis.
Analysis of prognostic factors
In a model of stepwise logistic regression, the relationships
between variables documented in the initial evaluation and
clinical response were assessed. Demographic and clinical
symptoms and the Simpliﬁed Acute Physiology Score (SAPS
II) served as possible prognostic factors. Variables that did not
fall short of the 5% threshold were eliminated in a stepwise
manner.
RESULTS
In total, 95 patients were included in the study
and randomised into either of the treatment arms.
Thirteen subjects were subsequently excluded
from the ITT population, and another 12 patients
had to be excluded from the ATP population. In
eight cases, exclusion criteria were violated
(four patients with bronchial carcinoma, three
patients with tuberculosis, one patient with pleu-
ral empyema); six patients received antimicrobial
treatment not in accordance with the study
protocol; in six patients, the total duration of
therapy was less than required; and ﬁve patients
were lost during follow-up.
The proportion of males was highest among
patients receiving ampicillin + sulbactam. Other
patient characteristics and concomitant diseases
were comparable in both treatment arms, and are
listed in Table 1. One patient in the clindamycin
group was younger than the required 18 years,
but was nevertheless included after careful delib-
eration.
Antimicrobial treatment
In the clindamycin ATP group, 24 (72.7%) patients
received a cephalosporin initially in addition
to clindamycin. Cephalosporins were adminis-
tered parenterally. Cefotiam (n ¼ 12), cefuroxime
(n ¼ 6), cefazolin (n ¼ 2), ceftazidime (n ¼ 2),
cefotaxime (n ¼ 1) and ceftriaxone (n ¼ 1) were
prescribed. Duration of therapy according to the
route of administration is shown in Table 2.
Bacteriological ﬁndings
Valid microbiological samples were obtained
from all 70 patients of the ATP group before
therapy. Samples were derived from protec-
ted specimen brush (n ¼ 55), bronchoalveolar
lavage (n ¼ 37), bronchoscopically obtained bron-
chial secretions (n ¼ 30), transthoracic puncture
(n ¼ 1), and sputum (n ¼ 109). Pathogens
(n ¼ 118) were identiﬁed in 58 patients, and are
listed in Table 3. A deﬁnite bacteriological diag-
nosis was achieved for 34 individuals. A pre-
sumptive cause of infection was found in three
cases in addition to a deﬁnite organism. Twenty-
six subjects had a single pathogen identiﬁed.
Mixed infection was present in 32 patients. In
16 cases, two different species were found; in
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11 patients, three different organisms were cul-
tured; four different species were isolated in three
subjects; and in one patient each, six and seven
causative bacteria were identiﬁed.
Clinical response
With ampicillin + sulbactam, cure or improve-
ment occurred in 27 (73.0%) patients at the end of
therapy, and in 25 (67.5%) subjects by the ﬁnal
examination. In 22 (66.7%) subjects receiving
clindamycin, pneumonia was considered to be
cured or improved at the end of therapy, and in
21 (63.6%) at the ﬁnal examination. The statistical
evaluation is shown in Table 4.
Bacteriological response
The bacteriological response was evaluated in
44 subjects. Statistical assessment of the therapeu-
tic equivalence of both medications in terms of
bacteriological response gave inconclusive results
because of the low number of cases. Therapy
failed in one patient in each study arm, and was
discontinued because of bacterial resistance, with
Pseudomonas aeruginosa being present in both
patients, and Stenotrophomonas maltophilia being
additionally isolated from one patient. These
organisms were present before therapy.
Premature discontinuation and adverse events
In the ITT group, 46 (56.1%) of 82 patients
completed a full course of therapy. Two subjects
from the ampicillin + sulbactam ITT population
(n ¼ 41) experienced mild-to-moderate adverse
events (e.g., skin eruption, diarrhoea) that were
probably related to the study medication. One
individual from the ampicillin + sulbactam group
developed a severe adverse event with increasing
mucous obstruction and respiratory insufﬁciency
leading to death. In two subjects from the clinda-
mycin ITT group (n ¼ 41), therapy was discon-
tinued because of adverse events. One individual
experienced drug-related skin eruption; in an-
other subject, the study was terminated because
Table 2. Duration of antibacterial
therapy in aspiration pneumonia
and primary lung abscessRoute of
administration
Ampicillin + sulbactam
mean ± SD
in days (range)
Clindamycin
mean ± SD
in days (range)
Cephalosporin
mean ± SD
in days (range)
Intravenous 7.6 ± 2.42
(6–91)
8.6 ± 4.3
(3–20)
11.0 ± 6.85
(3–29)
Oral 21.0 ± 20.94
(2–78)
24.6 ± 25.69
(1–91)
–
Combined 22.7 ± 20.83
(6–91)
24.1 ± 24.2
(3–98)
11.0 ± 6.85
(3–29)
Table 1. Characteristics of patients
treated according to protocol, under-
lying conditions predisposing to
aspiration and concomitant p values
in Fisher’s exact test
Characteristics
Ampicillin +
sulbactam
(n = 37) n (%)
Clindamycin
(n = 33)
n (%) p value
Mean age in years (range) 57.8 (18–90) 62.2 (17–90) 0.35
Male 32 (86.5) 21 (63.6) 0.05
Antibiotics before study 16 (43.2) 9 (27.3) 0.21
Community-acquired disease 28 (75.5) 27 (81.8) 0.57
Underlying conditions
Any underlying condition 35 (94.6) 31 (93.9) 1.0
Cardiovascular disease 18 (48.6) 19 (57.6) 0.48
Hypertension 7 (18.9) 10 (30.3) 0.40
Ischaemic heart disease 9 (24.3) 5 (15.2) 0.38
Heart failure 9 (24.3) 8 (24.2) 1.0
Mental disorder 7 (18.9) 2 (6.1) 0.16
Disorder of digestive system 10 (27.0) 5 (15.2) 0.26
Pulmonary disease 11 (29.7) 17 (51.5) 0.09
COPD 6 (16.2) 8 (24.2) 0.55
Diabetes mellitus 5 (13.5) 4 (12.1) 1.0
COPD, chronic obstructive pulmonary disease.
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of recurrent grand mal seizures and recurrent
fever. Treatment failure leading to premature
discontinuation occurred in eight (19.5%) subjects
of the ampicillin + sulbactam group and in ten
(24.4%) patients receiving clindamycin. All other
patients in whom treatment was discontinued
prematurely were either non-compliant with
therapy or were lost during follow-up.
Prognostic factors
Regarding clinical response, the SAPS II score was
found to be a predictive factor in patients with
aspiration pneumonia in a stepwise regression
Table 3. Anaerobic and aerobic pathogens recovered from
patients with aspiration pneumonia and primary lung
abscess at baseline
Isolates No. of casesa
Anaerobesb 25
Peptostreptococcus spp. 5
Peptococcus spp. 1
Prevotella spp. 2
Prevotella intermedia 2
Prevotella buccae 2
Prevotella melaninogenica 3
Fusobacterium nucleatum 1
Bacteroides spp. 2
Others 7
Aerobes and facultative aerobes 93 (51)
Gram-positives 51 (28)
Staphylococcus aureus 14 (9)
Streptococcus spp. 17 (10)
Streptococcus pneumoniae 6 (4)
Streptococcus milleri 2 (2)
Others 12 (2)
Gram-negatives 42 (23)
Escherichia coli 5 (3)
Klebsiella pneumoniae 2 (1)
Klebsiella oxytoca 3 (2)
Haemophilus spp. 2
Haemophilus inﬂuenzae 2 (2)
Haemophilus parainﬂuenzae 3 (3)
Pseudomonas spp. 3 (2)
Pseudomonas aeruginosa 3 (1)
Acinetobacter spp. 2 (2)
Enterobacter spp. 3 (1)
Proteus spp. 5 (1)
Pasteurella multocida 1 (1)
Neisseria spp. 3 (2)
Stenotrophomonas maltophilia 1
Others 4 (2)
aNumbers include deﬁnite and presumptive causative
pathogens; numbers of deﬁnite causative pathogens are
given in parentheses.
bAnaerobic bacteria were recovered only from protected
specimen brush and bronchoalveolar lavage specimens.
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analysis. The mean SAPS II scores at baseline
were 22.2 points (range 6–47, median 19) in the
ampicillin + sulbactam group, and 30.1 (range
0–163, median 22) in the clindamycin group. As
this factor appeared to be unevenly distributed
between the two treatment groups, exploratory
stratiﬁed adjusted analysis was performed. The
SAPS II score was categorised into one group with
£ 30 points and another group with > 30 points.
The results of the adjusted stratiﬁed analysis
reproduced the ﬁndings of the non-adjusted
analysis. The somewhat higher score in the
clindamycin group was mainly caused by the
high score of a single subject. The rate of thera-
peutic failures in the category with > 30 points
was higher in both treatment arms compared to a
score of 30.
Mortality
Nine (12.9%) patients of the ATP population died
during the course of the study; seven were
receiving clindamycin, while two were receiving
ampicillin + sulbactam. Five patients died from
acute heart failure, two subjects from respiratory
insufﬁciency, and one individual each from pul-
monary embolism and acute stroke. All deaths
occurred in patients with a SAPS II score of
> 30 points.
DISCUSSION
Aspiration is considered to be the leading cause of
anaerobic pneumonia and primary lung abscess.
Coverage of anaerobic bacteria is an import-
ant requirement in the antibacterial treatment
of aspiration pneumonia. Ampicillin plus the
b-lactamase inhibitor sulbactam, compared to
clindamycin with the optional addition of a
second- or third-generation cephalosporin, was
equally effective in terms of clinical response,
with cure or improvement being achieved in more
than two-thirds (70.0%) of patients. Statistical
evaluation with a one-sided Farrington–Manning
test demonstrated a marginal advantage for amp-
icillin + sulbactam at a 10% equivalence range,
but both regimens were equally effective at a 15%
equivalence range. Both antibacterial regimens
were well-tolerated, with premature discon-
tinuation in only three ITT subjects. Stepwise
regression analysis of potential predictors of
unfavourable outcome of therapy only identiﬁed
the SAPS II score as signiﬁcant. All nine patients
who died during the observation period had a
SAPS II score of > 30 points, whereas there were
signiﬁcantly fewer therapeutic failures among
patients with 30 points.
In most early studies, anaerobes were recov-
ered in a high number of cases by representative
techniques such as transtracheal aspiration [5,6].
In this investigation, the number of anaerobic
pathogens isolated was relatively low, probably
because of the high number of patients treated
with various antibiotic regimens before inclusion
in this study. It is well known that antimicrobial
therapy rapidly alters the cultivable ﬂora, even if
valid specimens are obtained [5]. Although the
pivotal role of anaerobes is widely but not
universally accepted [14], the role of aerobic
microbes is controversial [11]. Some reports
suggest that lung abscess caused by aerobic
pathogens through non-aspiration events should
be considered as a separate entity [15]. There is
evidence that aerobic pathogens play an active
role in the disease rather than being commen-
sals, supporting the approach taken in this study
in testing for aerobic bacteria to help direct
antimicrobial therapy. Hirshberg et al. [16]
showed that patients with lung abscess had
a worse prognosis if Pseudomonas aeruginosa,
Klebsiella pneumonia or Staphylococcus aureus were
involved. Unlike other forms of pneumonia,
several investigations support the view that
aspiration pneumonia is generally of mixed
aetiology. This is conﬁrmed by the present
ﬁndings, in which more than half of the patients
with a bacteriological diagnosis had at least two
causative organisms identiﬁed.
Since anaerobes are ubiquitous commensals of
the oral cavity, sputum and contamination-prone
bronchial aspirations are of no value in the eval-
uation of anaerobic lung infections. The superior
quality of specimens obtained by ﬁbreoptic
bronchoscopy, either bronchoalveolar lavage or
protected specimen brush specimens, is generally
accepted [6,17]. Despite the limitations of cultured
sputum and bronchial aspirates for anaerobic
diagnosis, these techniques were included in this
study solely for the identiﬁcation of aerobic
microorganisms, with the proviso that a repre-
sentative sample was obtained. Sputum sampling
and bronchial aspiration were particularly helpful
in directing therapy when the clinical condi-
tion prevented invasive diagnostic procedures.
168 Clinical Microbiology and Infection, Volume 10 Number 2, February 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 163–170
Nevertheless, bronchoscopic examination should
be attempted in all cases, since poststenotic
cavernous pneumonia or necrotising bronchogen-
ic carcinoma are important differential diagnoses
and have to be ruled out before therapy [18]. Four
patients from our study population were diag-
nosed with bronchogenic carcinoma and were
subsequently excluded from the investigation.
Compared to previous studies, the overall
response rate in this investigation appears to be
relatively low. Success rates of up to 95% were
published in early reports [6]. In a more recent
study, Gudiol et al. [10] reported satisfactory
clinical and radiological responses in 18 of
19 patients with anaerobic lung infection treated
with clindamycin, whereas only ten of 18 patients
treated with penicillin responded favourably to
therapy. Levinson et al. [9] described similar
results. Neither study reported underlying con-
ditions, severity of disease, or mortality. Most
(94%) of the patients in this study presented with
at least one underlying disease or a condition
predisposing to aspiration. The mortality rate in
this investigation was 12.9%, suggesting that this
population was more prone to lung abscess, or
suffering from a more severe course of the
disease. This assumption is supported by Mori
et al. [19], who reported 2.4%mortality in patients
with community-acquired lung abscess, com-
pared to a 66% mortality rate in cases of nosoco-
mial infection with a higher frequency of
underlying disease. Perlman et al. [20] pub-
lished similar results, with a single death in
57 patients with uncomplicated primary lung
abscess and 75% mortality in immunocompro-
mised patients.
One limitation of this investigation results from
the fact that it included patients with community-
acquired as well as hospital-acquired aspiration
pneumonia, with a potential distinct difference in
the pattern of pathogens involved [21]. Since
almost 80% of patients suffered from community-
acquired disease, these results may not suf-
ﬁciently reﬂect nosocomial aspiration, when
broader antimicrobial coverage, particularly of
enteric bacteria and P. aeruginosa, might be
required [21]. Further investigations addressing
this question appear to be necessary.
Although antibiotic treatment is considered the
primary therapeutic option for aspiration pneu-
monia and lung abscess, the value of surgical
procedures for drainage of lung abscesses or
resection of affected lung compartments has been
discussed, either as an additional measure to
antibacterial treatment or as an alternative if
conservative therapy fails [22,23]. This multicen-
tre study was not intended to include follow-up
of patients who did not respond sufﬁciently
to antibacterial therapy. Nevertheless, of the
24 individuals from the ﬁrst author’s institution,
none required additional or subsequent surgical
procedures. Interestingly, the mean duration of
study medication in this institution was signiﬁ-
cantly higher—43.2 days for ampicillin + sulbac-
tam and 46.9 days for clindamycin—than the
average duration of therapy in all institutions,
and clinical cure or improvement was achieved in
87.5% of study subjects at the end of therapy.
These ﬁndings support our view that, apart from
severe and rare complications such as recurrent
haemoptysis, persisting bronchopleural ﬁstulas or
empyema, antibiotic therapy is the treatment of
choice for lung abscess, on the condition that
antibacterials are administered for a sufﬁcient
period of time.
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